Novaremed
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Teichgaesslein 9, Basel, Basel-City, 405...Phone Number
+41 792075715Website
www.novaremed.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Novaremed
Novaremed AG is a clinical-stage biopharmaceutical company focused on innovating chronic pain management through the development of non-opioid treatment options. Their lead product, nispomeben, is an orally active small molecule currently undergoing Phase 2b clinical trials for treating painful diabetic peripheral neuropathy (PDPN). The company also has a pipeline candidate, MP-101, aimed at preventing chemotherapy-induced peripheral neuropathy (CIPN). Novaremed targets patients suffering from chronic pain associated with diabetes and cancer chemotherapy, addressing significant unmet medical needs in these areas.Explore more
Novaremed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novaremed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Novaremed is spiking on competitors!
Website visits: Recent activity has been detected on your website
Novaremed, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Novaremed had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Novaremed has new funding data
Earning: See what the market has to say on Novaremed recently announced quarterly report
Product Launch: Get notified when Novaremed launches new products
Congratulate Masked Content for being promoted to Masked Content at Novaremed
Check if Novaremed has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Novaremed as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Novaremed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novaremed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novaremed.
Novaremed financials insights
Gather financial insights about Novaremed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$2.7M
2021
Unspecified
$50M
Novaremed Tech Stack
A closer look at the technologies used by Novaremed
Most Recent Scoops
Mergers & Acquisitions (M&A)
Funding
Funding
Funding
Funding
Novaremed News & Media
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy
Basel, Switzerland, 6 May 2025 – Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces that recruitment is completed in the National Institutes of Health (NIH) -sponsored Phase 2b EN21-01 trial (ClinicalTrials.gov identifier NCT05480228). The study evaluates Novaremed’s non-opioid investigational drug NRD.E1 for the treatment of chronic pain associated with diabetic peripheral neuropathy, and is funded by the NIH Helping to End Addiction Long-term Initiative, or NIHNovaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment
BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a privately held clinical-stage biopharmaceutical company focused on innovative non-opioid treatment options for chronic pain management announces the simultaneous publication of data from three Phase 1 studies in Clinical Pharmacology in Drug Development and one Phase 2a, placebo-controlled, dose-finding, proof of concept study in European Journal of Pain with the Company’s lead investigational drug candidate NRD.E1, an innovative non-opioid tLe composé phare non opioïde de Novaremed, le NRD.E1, sera testé dans le cadre de l’essai de Phase 2 de l’initiative NIH HEAL pour le traitement de la douleur chronique
BÂLE, Suisse--(BUSINESS WIRE)--Novaremed AG, une société biopharmaceutique privée au stade clinique, annonce la réalisation d’une étude en collaboration avec les National Institutes of Health (NIH), dans le cadre de laquelle les NIH parraineront et dirigeront une étude clinique de Phase 2b sur le NRD.E1, le composé non opioïde en développement de Novaremed pour le traitement de la neuropathie diabétique périphérique douloureuse (DPN). Après un examen approfondi par des spécialistes de la douleuNovaremed’s Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain
BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces a study with the National Institutes of Health (NIH) under which the NIH will sponsor and conduct a clinical Phase 2b study with Novaremed’s lead non-opioid development compound NRD.E1 in the treatment of painful diabetic peripheral neuropathy (PDPN). After a thorough review by pain experts, Novaremed has received NIH confirmation for funding and execution of a Phase 2b study
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novaremed
Sign Up For FreeTo access detailed company insights
Novaremed AG is a clinical-stage biopharmaceutical company focused on innovating chronic pain management through the development of non-opioid treatment options. Their lead product, nispomeben, is an orally active small molecule currently undergoing Phase 2b clinical trials for treating painful diabetic peripheral neuropathy (PDPN). The company als... Read More
